Technical Analysis for ABUS - Arbutus Biopharma Corporation

Grade Last Price % Change Price Change
D 3.96 2.99% 0.12
ABUS closed up 2.99 percent on Friday, November 1, 2024, on 48 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 5
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Stochastic Reached Oversold Weakness 0.00%
Outside Day Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish 2.99%
Down 3 Days in a Row Weakness 2.99%
Fell Below 20 DMA Bearish 0.51%
Fell Below 50 DMA Bearish 0.51%
MACD Bearish Signal Line Cross Bearish 0.51%
180 Bearish Setup Bearish Swing Setup 0.51%

   Recent Intraday Alerts

Alert Time
Rose Above 20 DMA about 21 hours ago
Up 1 ATR about 21 hours ago
Rose Above Previous Day's High about 21 hours ago
20 DMA Resistance about 21 hours ago
Outside Day about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Arbutus Biopharma Corporation Description

Arbutus Biopharma Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics, and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. The company's products for Hepatitis B virus (HBV) comprise TKM-HBV, a RNAi therapeutic in Phase I clinical trial; OCB-030, a cyclophilin inhibitor drug candidate; CYT-003, a TLR9 agonist; capsid assembly inhibitors for use as oral therapeutics; surface antigen secretion inhibitors; STING agonists, a stimulator of interferon genes research program; cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; and cccDNA epigenetic modifiers, a research program to inhibit the formation of new virus and subviral particles from cccDNA. Its products also include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-Ebola, an anti-ebola viral therapeutic in Phase I clinical trial; and TKM-Ebola-Guinea, an anti-ebola RNAi therapeutic in Phase 2 trial. In addition, the company develops TKM-Marburg to treat Marburg infections; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02, a therapeutic targeting transthyretin amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in August 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Infectious Diseases Alcohol Gastrointestinal Hydrogen Hepatitis B Lipid Cholesterol Metabolism Carcinoma Amyloid Amyloidosis Hepatitis B Virus Hepatocellular Carcinoma Interferon Hypercholesterolemia Rna Interference Acute Lymphoblastic Leukemia Cyclophilin Ebola Liver Cancer Neuroendocrine Tumors Transthyretin Neuroendocrine Tumor PLK1 Pharmaceutical Partners Triglyceride Tropical Diseases Zoonoses Sexually Transmitted Diseases And Infections Tlr9 Transthyretin Amyloidosis

Is ABUS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.725
52 Week Low 1.7
Average Volume 1,166,493
200-Day Moving Average 3.29
50-Day Moving Average 4.03
20-Day Moving Average 3.97
10-Day Moving Average 4.00
Average True Range 0.14
RSI (14) 48.72
ADX 15.41
+DI 18.00
-DI 23.74
Chandelier Exit (Long, 3 ATRs) 3.92
Chandelier Exit (Short, 3 ATRs) 4.11
Upper Bollinger Bands 4.24
Lower Bollinger Band 3.69
Percent B (%b) 0.48
BandWidth 13.85
MACD Line 0.00
MACD Signal Line 0.01
MACD Histogram -0.0112
Fundamentals Value
Market Cap 664.07 Million
Num Shares 168 Million
EPS -0.46
Price-to-Earnings (P/E) Ratio -8.61
Price-to-Sales 21.53
Price-to-Book 3.88
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.25
Resistance 3 (R3) 4.22 4.11 4.20
Resistance 2 (R2) 4.11 4.03 4.12 4.18
Resistance 1 (R1) 4.03 3.99 4.07 4.06 4.17
Pivot Point 3.92 3.92 3.94 3.93 3.92
Support 1 (S1) 3.84 3.84 3.88 3.86 3.75
Support 2 (S2) 3.73 3.80 3.74 3.74
Support 3 (S3) 3.65 3.73 3.72
Support 4 (S4) 3.67